• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

司库奇尤单抗治疗斑块状银屑病期间原发性活动性肺结核的罕见病例报告

Rare Case Report of Primary Active Pulmonary Tuberculosis During Ixekizumab Treatment for Plaque Psoriasis.

作者信息

Li Yuan, Lu Jiejie, Fu Jingqiu

机构信息

Department of Cosmetic Dermatology, The Fifth People's Hospital of Hainan Province, Haikou, Hainan, People's Republic of China.

出版信息

Clin Cosmet Investig Dermatol. 2024 Jul 31;17:1723-1728. doi: 10.2147/CCID.S475486. eCollection 2024.

DOI:10.2147/CCID.S475486
PMID:39100253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11298185/
Abstract

Biologic agents have become a mainstay in the treatment of psoriasis, particularly in moderate to severe, refractory, and special types of the disease. Among these, ixekizumab is a humanized IgG4 monoclonal antibody targeting interleukin-17A, approved for the treatment of moderate to severe plaque psoriasis. Its adverse effects include infections such as nasopharyngitis, upper respiratory tract infections, and injection site reactions. While the incidence of tuberculosis (TB) associated with IL-17A antagonists is extremely low, this paper reports a case of active pulmonary tuberculosis occurring after ten doses of ixekizumab treatment for chronic plaque psoriasis. This highlights the importance for clinicians to remain vigilant regarding tuberculosis infection in patients undergoing therapy with this class of medications, emphasizing the need for enhanced screening and monitoring for tuberculosis during treatment.

摘要

生物制剂已成为治疗银屑病的主要手段，尤其是在中重度、难治性及特殊类型的银屑病治疗中。其中，司库奇尤单抗是一种靶向白细胞介素-17A的人源化IgG4单克隆抗体，已被批准用于治疗中重度斑块状银屑病。其不良反应包括感染，如鼻咽炎、上呼吸道感染以及注射部位反应。虽然与白细胞介素-17A拮抗剂相关的结核病发病率极低，但本文报告了1例慢性斑块状银屑病患者在接受10剂司库奇尤单抗治疗后发生活动性肺结核的病例。这凸显了临床医生在使用这类药物治疗患者时对结核感染保持警惕的重要性，强调了在治疗期间加强结核病筛查和监测的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3acd/11298185/d9c29d36c689/CCID-17-1723-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3acd/11298185/02b942dcab0c/CCID-17-1723-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3acd/11298185/ac13346fdcc0/CCID-17-1723-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3acd/11298185/d9c29d36c689/CCID-17-1723-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3acd/11298185/02b942dcab0c/CCID-17-1723-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3acd/11298185/ac13346fdcc0/CCID-17-1723-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3acd/11298185/d9c29d36c689/CCID-17-1723-g0003.jpg

相似文献

1
Rare Case Report of Primary Active Pulmonary Tuberculosis During Ixekizumab Treatment for Plaque Psoriasis.司库奇尤单抗治疗斑块状银屑病期间原发性活动性肺结核的罕见病例报告
Clin Cosmet Investig Dermatol. 2024 Jul 31;17:1723-1728. doi: 10.2147/CCID.S475486. eCollection 2024.
2
Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.司库奇尤单抗用于治疗中度至重度斑块状银屑病和银屑病关节炎的成人患者。
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1423-1433. doi: 10.1080/17512433.2016.1242409. Epub 2016 Oct 11.
3
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.无需改变药物类别：在银屑病中，司库奇尤单抗治疗后使用依奇珠单抗。
J Dermatolog Treat. 2019 May;30(3):216-220. doi: 10.1080/09546634.2018.1506081. Epub 2018 Sep 11.
4
Emerging targeted therapies for plaque psoriasis - impact of ixekizumab.斑块状银屑病的新兴靶向疗法——司库奇尤单抗的影响
Clin Cosmet Investig Dermatol. 2017 Apr 21;10:133-139. doi: 10.2147/CCID.S111007. eCollection 2017.
5
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).在一项针对中度至重度斑块状银屑病儿科患者的III期随机双盲安慰剂对照研究（IXORA-PEDS）中，司库奇尤单抗的疗效和安全性。
Br J Dermatol. 2020 Aug;183(2):231-241. doi: 10.1111/bjd.19147. Epub 2020 Jun 15.
6
Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials.依奇珠单抗治疗银屑病：III 期临床试验综述。
Dermatol Ther (Heidelb). 2016 Mar;6(1):25-37. doi: 10.1007/s13555-016-0102-0. Epub 2016 Feb 24.
7
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge.依奇珠单抗治疗银屑病的药物安全性评价：对现有知识的综述。
Expert Opin Drug Saf. 2022 Oct;21(10):1249-1257. doi: 10.1080/14740338.2022.2134855. Epub 2022 Oct 31.
8
Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.司库奇尤单抗：一种用于治疗中度至重度斑块状银屑病的新型抗白细胞介素-17A单克隆抗体疗法。
Expert Opin Biol Ther. 2016;16(2):255-63. doi: 10.1517/14712598.2016.1132695. Epub 2016 Jan 25.
9
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.中度至重度斑块状银屑病患者中，ixekizumab与guselkumab的头对头比较：一项随机双盲试验的12周疗效、安全性及反应速度
Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15.
10
Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis.依奇珠单抗：用于治疗中度至重度斑块型银屑病的研究进展。
Ann Pharmacother. 2019 Mar;53(3):276-284. doi: 10.1177/1060028018799982. Epub 2018 Sep 6.

本文引用的文献

1
Lung IL-17A-Producing CD4 T Cells Correlate with Protection after Intrapulmonary Vaccination with Differentially Adjuvanted Tuberculosis Vaccines.肺内产生白细胞介素-17A的CD4 T细胞与不同佐剂结核疫苗肺内接种后的保护作用相关。
Vaccines (Basel). 2024 Jan 26;12(2):128. doi: 10.3390/vaccines12020128.
2
Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study.Ixekizumab 在中国中重度斑块型银屑病成人患者中的安全性和疗效：一项前瞻性、多中心、观察性研究。
Adv Ther. 2023 Dec;40(12):5464-5474. doi: 10.1007/s12325-023-02672-1. Epub 2023 Oct 12.
3
An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients.
银屑病患者炎症性肠病与白细胞介素-17抑制剂生物治疗之间可能关联的见解。
Pharmaceutics. 2023 Aug 21;15(8):2171. doi: 10.3390/pharmaceutics15082171.
4
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.在美国使用古塞库单抗、阿达木单抗、司库奇尤单抗或依奇珠单抗进行银屑病的长期控制。
Dermatol Ther (Heidelb). 2023 Apr;13(4):1053-1068. doi: 10.1007/s13555-023-00910-6. Epub 2023 Mar 16.
5
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program.COAST 计划：依奇珠单抗治疗中轴型脊柱关节炎 3 年的长期安全性和疗效数据。
J Rheumatol. 2023 Aug;50(8):1020-1028. doi: 10.3899/jrheum.221022. Epub 2023 Feb 15.
6
Risk of cancer, tuberculosis and serious infections in patients with ankylosing spondylitis, psoriatic arthritis and psoriasis treated with IL-17 and TNF-α inhibitors: a nationwide nested case-control analysis.IL-17 和 TNF-α 抑制剂治疗的强直性脊柱炎、银屑病关节炎和银屑病患者的癌症、结核病和严重感染风险：一项全国性巢式病例对照分析。
Clin Exp Rheumatol. 2023 Jul;41(7):1491-1499. doi: 10.55563/clinexprheumatol/qkiorp. Epub 2022 Dec 5.
7
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.药物生存与 Guselkumab、Ixekizumab、Secukinumab、Ustekinumab 和 Adalimumab 在银屑病患者中的治疗有效性和安全性相关。
JAMA Dermatol. 2022 Oct 1;158(10):1131-1141. doi: 10.1001/jamadermatol.2022.2909.
8
IL-17 and IL-17-producing cells in protection versus pathology.白细胞介素-17 及其产生细胞在保护与病理中的作用。
Nat Rev Immunol. 2023 Jan;23(1):38-54. doi: 10.1038/s41577-022-00746-9. Epub 2022 Jul 5.
9
Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection.用于银屑病关节炎的司库奇尤单抗：安全性、疗效及患者选择
J Inflamm Res. 2021 Dec 17;14:6975-6991. doi: 10.2147/JIR.S229752. eCollection 2021.
10
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications.细胞因子介导的银屑病分子病理生理学及其临床意义。
Int J Mol Sci. 2021 Nov 26;22(23):12793. doi: 10.3390/ijms222312793.